


PRODUCT INFORMATION



Chloramphenicol Succinate

Item No. 25453

CAS Registry No.: 3544-94-3
Formal Name: butanedioic acid, mono[(2R,3R)-2-[(dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl] ester
MF: C₁₅H₁₆Cl₂N₂O₈
FW: 423.2
Purity: ≥99%
UV/Vis.: λ_{max}: 273 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Chloramphenicol succinate is supplied as a solid. A stock solution may be made by dissolving the chloramphenicol succinate in the solvent of choice, which should be purged with an inert gas. Chloramphenicol succinate is soluble in ethanol, methanol, DMSO, and dimethyl formamide. We do not recommend storing the aqueous solution for more than one day.

Description

Chloramphenicol succinate is a water-soluble prodrug form of the antibiotic chloramphenicol.¹ It is a substrate for succinate dehydrogenase (SDH) and is oxidized by human liver and rat liver and kidney mitochondria to release chloramphenicol *in vitro*.² Chloramphenicol succinate reduces human leukocyte migration *in vitro*.³ *In vivo*, chloramphenicol succinate reduces *E. coli* growth in rabbit and rat models of pyelonephritis when administered at doses of 150 and 200 mg/kg, respectively.⁴ Chloramphenicol succinate (20 mg/kg) reduces infarct size in a porcine model of myocardial ischemia-reperfusion injury.⁵ Formulations containing chloramphenicol succinate have been used in the treatment of severe bacterial infections.

References

1. Ceriotti, G., Defranceschi, A., De Carneri, I., *et al.* Chloramphenicol succinate, a water-soluble derivative of chloramphenicol. *Farmaco Sci.* **9(1)**, 21-38 (1954).
2. Ambekar, C.S., Lee, J.S., Cheung, B.M., *et al.* Chloramphenicol succinate, a competitive substrate and inhibitor of succinate dehydrogenase: Possible reason for its toxicity. *Toxicol. In Vitro* **18(4)**, 441-447 (2004).
3. Forsgren, A. and Schmeling, D. Effect of antibiotics of chemotaxis of human leukocytes. *Antimicrob. Agents Chemother.* **11(4)**, 590-584 (1977).
4. Prat, V., Konickova, L., Ritzerfeld, W., *et al.* Effect of chloramphenicol against different *E. coli* strains in vitro and in experimental pyelonephritis. *Arzneimittelforschung* **18(9)**, 1123-1127 (1968).
5. Sala-Mercado, J.A., Wider, J., Undyala, V.V., *et al.* Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia-reperfusion injury. *Circulation* **122(11 Suppl)**, S179-S184 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM